— Know what they know.
Not Investment Advice
Also trades as: EMBCV (NASDAQ) · $vol 116M

EMBC NASDAQ

Embecta Corp.
1W: +5.7% 1M: -64.0% 3M: -68.6% YTD: -71.1% 1Y: -72.0% 3Y: -87.2%
$3.32
+0.00 (+0.00%)
 
Weekly Expected Move ±29.4%
$1 $2 $3 $4 $5
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · Alpha Radar Strong Sell · Power 29 · $197.0M mcap · 58M float · 2.95% daily turnover · Short 51% of daily vol

Cash Flow Trends

Operating Cash Flow
$192M +437.0% ▲
5Y CAGR: -17.4%
Capital Expenditures
$9M +41.1% ▲
5Y CAGR: -26.0%
Free Cash Flow
$182M +816.6% ▲
5Y CAGR: -16.8%
Dividends Paid
$35M -1.4% ▼
Buybacks
$6M -90.0% ▼
Net Change in Cash
-$46M +12.8% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income$415M$224M$70M$78M$95M
Depreciation & Amort.$38M$32M$33M$36M$41M
Stock-Based Comp.$13M$19M$22M$26M$32M
Change in Working Capital-$32M$92M-$80M-$48M-$24M
Other Non-Cash Items$24M$72M$9M$13M$30M
Operating Cash Flow$456M$412M$68M$36M$192M
— Investing Activities —
Capital Expenditures-$39M-$24M-$26M-$16M-$9M
Acquisitions (Net)$0$0$0$0$0
Investment Purchases$0$0$0$0$0
Investment Sales$0$0$0$0$0
Other Investing$0$0$0$0$0
Investing Cash Flow-$39M-$24M-$26M-$16M-$9M
— Financing Activities —
Net Debt Issuance$0$1.4B-$11M-$36M-$186M
Stock Repurchased$0$0-$4M-$3M-$6M
Dividends Paid$0-$9M-$34M-$34M-$35M
Other Financing-$417M-$1.5B$0$0$0
Financing Cash Flow-$417M-$48M-$49M-$73M-$227M
Net Change in Cash$0$331M-$4M-$52M-$46M
Cash End of Period$0$331M$326M$274M$229M
Free Cash Flow$417M$388M$41M$20M$182M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms